10-Q Filing

SOLENO THERAPEUTICS INC CIK: 1484565 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0001564590-22-028965`
Period End Date	20220630
Filing Date	20220810
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	slno-10q_20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 58 Income Statement 61 Cash Flow Statement 54 Stockholders Equity 29

Balance Sheet 58 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	79.86M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	120.09M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	79.86M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	120.09M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$21.30M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$24.07M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.12M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$824.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$22.42M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$24.89M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$28.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$33.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$600.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$421.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$279.00K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$12.64M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$11.66M	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$40.00K	USD	Point-in-time
Total assets	`Assets`	$35.55M	USD	Point-in-time
Total assets	`Assets`	$36.86M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.41M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.25M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$932.00K	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$728.00K	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.16M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.42M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$282.00K	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$337.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$323.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$415.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$8.01M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.25M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$9.30M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$9.55M	USD	Point-in-time
Long-term lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$175.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$17.76M	USD	Point-in-time
Total liabilities	`Liabilities`	$16.55M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value, 250,000,000 shares authorized, 120,088,816 and 79,864,310 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.	`CommonStockValue`	$120.00K	USD	Point-in-time
Common stock, $0.001 par value, 250,000,000 shares authorized, 120,088,816 and 79,864,310 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.	`CommonStockValue`	$80.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$231.07M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$245.99M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-213.35M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-225.80M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.00K	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$20.31M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$17.79M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$27.44M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$45.55M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$26.46M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$37.57M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$35.55M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$36.86M	USD	Point-in-time

Income Statement 61 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$3.70M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.59M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.68M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$12.75M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.46M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.11M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$5.44M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.47M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$3.03M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-242.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.05M	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$616.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$12.55M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$11.09M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$20.24M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$6.78M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-20.24M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-6.78M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-12.55M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-11.09M	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-56.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-29.00K	USD	2 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-257.00K	USD	2 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$41.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$74.00K	USD	2 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$52.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$42.00K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$97.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$299.00K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$54.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$103.00K	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.99M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-8.95M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-19.94M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	2 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-12.45M	USD	2 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-10.99M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-6.72M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-19.94M	USD	2 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.14	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-0.06	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-0.12	USD	2 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.25	USD	2 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.12	USD	2 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.06	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.14	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.25	USD	2 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	79.75M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	100.17M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	120.09M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	79.72M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	120.09M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	79.72M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	79.75M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	100.17M	shares	2 Qtrs

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-12.45M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-19.94M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$984.00K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$979.00K	USD	2 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$142.00K	USD	2 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$151.00K	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.95M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.22M	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-56.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-29.00K	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-257.00K	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$3.03M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-242.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.05M	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$616.00K	USD	1 Quarter
Other non-cash reconciling items	`OtherNonCashReconcilingItems`	$-1.00K	USD	2 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-334.00K	USD	2 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-83.00K	USD	2 Qtrs
Other Assets	`IncreaseDecreaseInOtherOperatingAssets`	$40.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-848.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-153.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$204.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-353.00K	USD	2 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$138.00K	USD	2 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$-264.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-120.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-168.00K	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$62.00K	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$92.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-15.50M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.98M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.00K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-7.00K	USD	2 Qtrs
Proceeds from sale of common stock and pre-funded warrants, net of costs	`ProceedsFromSaleOfCommonStockAndPreFundedWarrantsNetOfCosts`	$13.77M	USD	2 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$120.00K	USD	2 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	2 Qtrs
Principal paid on finance lease liabilities	`FinanceLeasePrincipalPayments`	$3.00K	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-123.00K	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$13.75M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.76M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-15.63M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$24.07M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$33.60M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.22M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$24.07M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$33.60M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.22M	USD	Point-in-time
Right-of-use assets obtained in exchange for operating lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$581.00K	USD	2 Qtrs
Deferred financing costs included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$12.00K	USD	2 Qtrs

Stockholders Equity 29 line items

Line Item	Tag	Value	Unit	Period
Less transaction costs	`PaymentsOfStockIssuanceCosts`	$1.03M	USD	1 Quarter
Balances at beginning	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$27.44M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$45.55M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$37.57M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$571.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.09M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$644.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$857.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$120.00K	USD	1 Quarter
Sale of common stock and pre-funded warrants in public offering, net of costs of $1,034	`StockIssuedDuringPeriodValueNewIssues`	$13.77M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.99M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-8.95M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-19.94M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	2 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Balances at ending	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$27.44M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$45.55M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$37.57M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.